Zhang Jiale, He Jingkai, Hu Jieqiong, Ji Yunxin, Lou Zhongze
Department of Psychosomatic Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China; School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China.
Department of Psychosomatic Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China; Ningbo Key Laboratory of Nervous System and Brain Function, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China.
Asian J Psychiatr. 2025 Mar;105:104411. doi: 10.1016/j.ajp.2025.104411. Epub 2025 Feb 21.
Depression is a common clinical mental disorder characterized by persistent low mood and anhedonia. It has become a major global public health issue due to its complex etiology and unclear mechanisms, resulting in limited diagnostic and therapeutic options. Recent studies indicate that dysbiosis of gut microbiota is closely related to the onset and progression of depression. This article systematically reviews the recent research on the 'microbiota-gut-brain axis' (MGBA), exploring the role and mechanisms of gut microbiota in preclinical and clinical studies. Additionally, it discusses the potential of modulating gut microbiota as a promising therapeutic approach for depression and suggests future research directions, aiming to provide a theoretical basis for research and clinical management of depression.
抑郁症是一种常见的临床精神障碍,其特征为持续的情绪低落和快感缺乏。由于其病因复杂、机制不明,它已成为一个重大的全球公共卫生问题,导致诊断和治疗选择有限。最近的研究表明,肠道微生物群失调与抑郁症的发生和发展密切相关。本文系统回顾了最近关于“微生物群-肠道-脑轴”(MGBA)的研究,探讨了肠道微生物群在临床前和临床研究中的作用及机制。此外,本文还讨论了调节肠道微生物群作为一种有前景的抑郁症治疗方法的潜力,并提出了未来的研究方向,旨在为抑郁症的研究和临床管理提供理论依据。